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a b s t r a c t 
This article describes data related to the research study en- 
titled “Duration of active psychosis during early phases of 
the illness and functional outcome: The PAFIP 10-year follow- 
up study.” [1]. We present data concerning the clinical and 
sociodemographic characteristics of a sample of drug-naïve 
patients with a first episode of non-affective psychosis. The 
dataset was obtained from a 3-year longitudinal interven- 
tion program as part of an ongoing 10-year epidemiological 
study. The tables and figure shown present the data from the 
analysis between the active psychosis (presence of positive 
psychotic symptoms), among other sociodemographic and 
clinical predictor variables, recorded during the 3-year longi- 
tudinal intervention program and the evaluation of the func- 
tional outcome (social functioning and functional recovery) 
∗ Corresponding author. 
E-mail address: g.pardosantayana@gmail.com (G. Pardo-de-Santayana). 
# Equal contributors. 
https://doi.org/10.1016/j.dib.2020.105599 
2352-3409/© 2020 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license. 
( http://creativecommons.org/licenses/by/4.0/ ) 
2 G. Pardo-de-Santayana, J. Vázquez-Bourgon and M. Gómez-Revuelta et al. / Data in Brief 30 (2020) 105599 
present at the 10-year mark. The data explores how those 
early parameters could influence long-term outcome. 
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a  Specifications Table 
Subject Psychiatry and Mental Health. 
Specific subject area Long-term outcome in first-episode psychosis. 
Type of data Tables and a figure. 
How data were acquired Prospective observational analytical study, including clinical evaluation. 
Data format Raw and analyzed. 
Parameters for data 
collection 
Drug-naïve patients with a first-episode of non-affective psychosis were included 
in a prospective observational analytical study (PAFIP) and treated with 
antipsychotics. Clinical examinations were carried out prospectively during a 
3-years follow-up period. A clinical and functional assessment was carried out 
after a 10-year period following inclusion in program. 
Description of data 
collection 
Psychotic symptoms were measured employing the 24-item Brief Psychiatric 
Rating Scale (BPRS), the Scale for the Assessment of Positive Symptoms (SAPS), 
the Scale for the Assessment of Negative Symptoms (SANS), the premorbid 
adjustment scale (PAS) and the Clinical Global Impression (CGI), among other 
clinical and sociodemographic surveys. Patients were seen frequently in our 
outpatient clinic and were granted rapid access if clinical exacerbations. 
Moreover, thorough examinations were carried out at baseline, 3 weeks, 6 
weeks, 3 months, 6 months, 12 months, 18 months, 24 months, 30 months, 36 
months and 10 years. 
Data source location Autonomous region of Cantabria, Spain. 
Data accessibility Repository name: Mendeley Data 
Data identification number: 10.17632/2crz5nd4w3.1 
Direct URL to data: http://dx.doi.org/10.17632/2crz5nd4w3.1 
Related research article Pardo-de-Santayana G, Vázquez-Bourgon J, Gómez-Revuelta M, Rosa Ayesa-Arriola 
R, Ortiz-Garcia de la Foz V, Crespo-Facorro B, Pelayo-Terán JM. (2020). Duration 
of active psychosis during early phases of the illness and functional outcome: 
The PAFIP 10-year follow-up study. Schizophrenia 
Research. https://doi.org/10.1016/j.schres.2020.03.009 
alue of the data 
• Exploring how early clinical and sociodemographic factors influence long-term social func-
tionality and functional recovery in first-episode psychosis could increase our understanding
of how improve their long-term outcome. 
• These data could benefit all those interested in treating or studying psychosis and how it
affects the long-term outcome of the patients who suffer it. 
• These data could be used for analyzing the progression of the clinical characteristics of pa-
tients undergoing a first-episode psychosis. 
. Data description 
We show in this article data derived from a study on the relation between active psy-
hosis (presence of positive psychotic symptoms), among other sociodemographic and clinical
ariables recorded during the 3-year longitudinal intervention program, and a cross-sectional
easurement of the functional outcome (social functioning and functional recovery) present 10-
ears after inclusion. These data were collected form a Spanish prospective observational an-
lytical study of drug-naïve patients with a first episode of non-affective psychosis [1] . Raw
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Table 1 
Logistic Regressions for Social Functioning 
Table 2 
















data has been made accessible through the public data repository “Mendeley Data” at http://
dx.doi.org/10.17632/2crz5nd4w3.1 
Table 1 describes the data of a logistic regression model for social functioning. The model ( χ ²:
42.091; p < 0.001; Nagelkerke R2: 0.335) included DAP (Duration of Active Psychosis; that mea-
sures the time from the initiation of positive psychotic symptomatology till its remission), mean
PAS (Premorbid Adjustment Scale), initial BPRS (Brief Psychiatric Rating Scale), initial negative
dimension, gender, hospitalization, educational level, unemployment at onset, active at onset
and diagnosis at 6 months. Mean PAS, initial BPRS and gender were the significant predictors.
Mean PAS was the main predictor of the logistic regression model (Wald: 17.560; p < 0.001). 
Table 2 describes the data of a logistic regression model for functional recovery. The model
( χ ²: 14.542; p = 0.002; Nagelkerke R2: 0.124) included DAP, mean PAS, hospitalization, socioeco-
nomic level, educational level, active at onset and diagnosis at 6 months. None were significant
predictors. 
Fig. 1 shows the ROC curves of DUP (Duration of Untreated Psychosis), DAT (Duration of psy- 
chosis After Treatment) and DAP (Duration of Active Psychosis) ROC curves for poor functional
recovery. None of the AUC were statistically significant. 
2. Experimental design, materials, and methods 
2.1. Population description 
To obtain these data we included in the analysis neuroleptic naïve adult patients with a first-
episode of non-affective psychosis from February 2001 to July 2008. They were included in a
3-year longitudinal intervention program as part of an ongoing 10-year epidemiological study
for first-episode psychosis (PAFIP) being conducted at the inpatient unit and outpatient clinic
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t the University Hospital Marques de Valdecilla, Spain. A detailed account of this program has
een described in a previous article [2] . 
Only after written informed consent were patients incorporated to the PAFIP program. The
rogram submits to the Declaration of Helsinki and was authorized by the local Institutional
eview Board, in compliance with international standards for research ethics. 
In the prospective observational analytical study from where these data were collected, we
ssessed the relationship of functional outcome with DUP (Duration of Untreated Psychosis), DAT
Duration of psychosis After Treatment) and DAP (Duration of Active Psychosis) in patients with
rst-episode non-affective psychosis. During a 3-year clinical follow-up, psychiatrists assessed
atients in a regular basis. Psychotic symptoms were rated employing the (SAPS) [3] , (SANS)
4] and (BPRS) [5] . The CGI scale was used to determine the evolution and severity of the symp-
oms [6] . Patients were seen frequently, based on their clinical status from weekly to quarterly
isits and had easy access to appointments in the event of the appearance of any symptom. Also,
valuations were carried out at baseline, 3 weeks, 6 weeks, 3 months, 6 months, 12 months, 18
onths, 24 months, 30 months and 36 months. After a 10-year period since inclusion in pro-
ram nother assessment was carried out. 
The duration of untreated psychosis (DUP) was defined as the time from the emergence of
rst continuous psychotic symptoms to introduction of adequate antipyschotic treatment. The
ate of the onset of the psychotic symptomatology was defined as the moment when first
ontinuous psychotic symptom appeared and was estimated using information from patients,
elatives and clinical records. To certify a systematically reliable measurement of the date of
sychotic onset, we gathered information through a semi-structured interview, elicited on the
ymptom Onset in Schizophrenia (SOS) inventory [7] and SCID deducing the date using the total
APS score ≥ 3 as the threshold. 
































The duration of active psychosis after treatment (DAT) was defined as the amount of time,
during the 3-year clinical follow-up, that a patient experienced active psychosis (positive psy-
chotic symptomatology) after initiation of antipsychotic medication. We recorded the amount of
time where patients had a score ≥ 3 on any of the four SAPS items. The duration of any psy-
chotic relapse or clinical exacerbation was added. Psychotic relapses were recorded in patients
who had previously achieved clinical remission (CGI rating ≤4, a reduction ≥ 30% on BPRS to-
tal score and having all BPRS key symptom items rated ≤3 for more than 4 consecutive weeks
during) [8] and was defined by any of the following criteria for at least 1 week of duration
[9,10] : (1) a rating of ≥ 5 on any key BPRS symptom items (2) CGI rating ≥ 6 and a change
in the CGI score of “much worse” or “very much worse”; (3) hospitalization for psychotic psy-
chopathology; (4) suicide [2–11] . Clinical exacerbations were defined as a 2-point increase on
any of the key BPRS symptoms (unusual thought content, hallucinations, suspiciousness, con-
ceptual disorganization and bizarre behavior), excluding all the cases where the rating remained
at the nonpsychotic level. 
Duration of Active Psychosis (DAP) was calculated by adding DUP and DAT for each patient
of the study. 
The measured sociodemographic variables were: premorbid adjustment scale (PAS) with the
recommendations of van Mastrigt and Addington for early psychosis [12] at childhood, early
and late adolescence, adulthood and the year before the onset of illness; occupational status
for 2 years prior to the initial interview (1. Employment/student; 2. Unemployed); housing ar-
rangements at the onset of psychosis (1. Living with relatives; 2. Living alone and other status);
gender; educational level (1. Primary education; 2. 10-years of education or higher). 
Social functioning was measured with the the Global Evaluation (GE) of the Disability As-
sessment Scale (DAS) [13] in the 10-year evalutation. Good social functioning was identified as
a score ≤ 1 on the GE, while a score ≥ 2 on the GE was considered poor social functioning. 
Functional recovery was measured in the 10-year evalutation and was defined as being in a
part-time/full-time job or studying while concomitantly having reached social functioning during
the at least the last 6 onths [2-14] 
3. Analysis 
Firstly we run a descriptive univariate analysis of social functioning and functional recovery
as dichotomous variables (good/poor social functioning and good/poorfunctional recovery). 
Secondly we conducted logistic regression models to predict social functioning and functional
recovery using DAP, together with the other significant predictors from the univariate analysis
were included at the start. 
We used receiver operating characteristic (ROC) curves to determine the area under the curve
(AUC) for DUP, DAT and DAP to estimate the capacity of theses variables to discriminate true
positives and false positives for poor functional recovery. 
The analysis was completed with SPSS, version 19.0 (SPSS Inc., Chicago, IL, USA). The statisti-
cal significance was set at 0.05 and in all cases we used two-tailed statistical test. 
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